Monoclonal antibody · Agonist of CD40 · developed by Apexigen America
Sotigalimab is a humanized monoclonal antibody that agonizes CD40, a TNF receptor superfamily member expressed on immune cells and some cancer cells. It mimics the endogenous CD40 ligand to activate antigen-presenting cells, B cells and T cells, and can also trigger apoptosis in CD40-expressing solid tumor cells. It is being studied in melanoma, glioblastoma and other CNS tumors, and pancreatic cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05419479 | Phase 1/2 | Pancreatic Cancer | Suspended | RCUS |
| NCT02706353 | Phase 1/2 | Melanoma | Terminated | PYXS |
| NCT03389802 | Phase 1 | Glioblastoma Multiforme | Completed | PYXS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Adenocarcinoma of the PancreasAdenosquamous Carcinoma of the PancreasCNS Primary Tumor, Not Otherwise Specified (NOS)Diffuse Intrinsic Pontine Gliomas (DIPG)Ependymoma, Not Otherwise Specified (NOS)Glioblastoma MultiformeHigh-grade Astrocytoma Not Otherwise Specified (NOS)MedulloblastomaMelanomaPancreatic CancerSquamous Cell Carcinoma of Pancreas
Updated Oct 25, 2026.